Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STERLING-WINTHROP ALZHEIMER’s DRUG DISCOVERY RESEARCH

Executive Summary

STERLING-WINTHROP ALZHEIMER's DRUG DISCOVERY RESEARCH is focusing on possible mechanisms of Alzheimer's that are independent of acetylcholine, the company said during the dedication of its new consolidated R&D center in Upper Providence Township, Penn. May 10. The Alzheimer effort is one of the newer and smaller projects in the company's redesigned research program. The "core" areas of research for Sterling will be imaging agents, chronic inflammation and oncology therapeutics, with the latter program focused on development of compounds discovered by the Cancer Treatment and Research Center in San Antonio. The firm also describes its endocrinology and cardiovascular programs as "smaller" efforts. Sterling-Winthrop unveiled its "renewed" pharmaceutical R&D pipeline in December ("The Pink Sheet" Dec. 21, 1992, p. 18). The nine-building R&D facility will house 1,200 researchers once construction is completed by the end of 1993, the company said. The first personnel began moving in during October. Sterling expects to have 2,000 researchers at the facility by the end of the decade. The facility includes laboratory and administration buildings as well as a pilot manufacturing facility to produce clinical supplies under GMP conditions and a drug safety assessment building. The campus is adjacent to Rhone-Poulenc Rorer's Collegeville headquarters. Sterling Winthrop Chairman Louis Mattis cited the 954,000 sq. ft. facility as evidence of "the commitment of our parent, the Eastman Kodak company" to its "vision of being a major participant in health care." Construction costs are estimated to be $365 mil.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel